ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., a contract development and manufacturing organization (CDMO), announced today that Peter Khoury, Ph.D. has joined the Company as Senior Vice President and Chief Commercial Officer, effective August 1, 2016.
“We are delighted to welcome Peter, a highly seasoned executive with proven sales and marketing skills, as our Chief Commercial Officer,” stated James M. Matthew, President, Chief Executive Officer and Chief Financial Officer of Nanotherapeutics, Inc. “Having worked in the healthcare and life sciences industries for more than 20 years with several of the largest, most influential and respected global organizations, Peter’s expertise and relationships make him a perfect fit for Nanotherapeutics. In this new position, Peter’s experience will be invaluable as we execute on our strategic plan, including an emphasis on commercial full-scale manufacturing, which is expected to significantly increase our customer base and revenue stream going forward.”
Dr. Khoury added, “Nanotherapeutics is an established CDMO with proprietary platform technologies and specialized infrastructure that provide its U.S. and international government and commercial customer base tangible and critical advantages in today’s marketplace. I am pleased to join the Company at this important juncture and look forward to working with the team to further expand its core capabilities and market share in key domestic and international markets.”
Before joining Nanotherapeutics, from 2014 until the present, Dr. Khoury was with the Bill & Melinda Gates Foundation, serving as Senior Program Officer, Life Science Partnerships, Office of the President for Global Health. Among his responsibilities, Dr. Khoury spearheaded the expansion of industry engagement with the developing country manufacturer (DCM) industry sector, including relationship management at the “C” level for strategically important and complex DCMs focused on life-saving initiatives including vaccines, biologicals, medical diagnostics and generic products.
Prior to his tenure with the Gates Foundation, from 2002 to 2012, Dr. Khoury was Vice President, Global Marketing at Baxter International, where he led the development and implementation of the company’s vaccines business strategies, product management, business plans, and ex-European vaccine sales. While there, Dr. Khoury also led global biosecurity and pandemic influenza sales and marketing, as well as government contracting efforts, solidifying key contracts with the U.S. Government and multiple foreign governments in addition to development programs with the Department of Health and Human Services, National Institutes of Health and National Institute of Allergy and Infectious Diseases.
Prior to his term at Baxter International, from 1993 to 2002, Dr. Khoury served in numerous positions of increasing responsibility in the marketing and sales organization at Merck & Co., Inc., with his last position as Director, Database and Direct Marketing.
Dr. Khoury earned his Bachelor’s degree in Biology and Ph.D. in Microbiology from Syracuse University, and received his Master’s in Business Administration in General Management/Marketing from Cornell University’s Johnson Graduate School of Management.
About Nanotherapeutics, Inc.
Nanotherapeutics is a contract development and manufacturing organization (CDMO) that operates a U.S.-based 180,000 square foot, state of the art, single-use, multi-purpose-multi-product, BSL-3 capable facility offering clients extensive capabilities, including a pilot facility for performing optimization of upstream, downstream and formulation functions, bulk cGMP manufacturing, and analytical development for proteins, antibodies, viral vaccines and gene therapy drug products. The Company provides expertise from preclinical through FDA licensure in a variety of production platforms, including microbial and mammalian cell culture. The Company also owns a second, Czech Republic-based, 160,000 square foot, 6,000-liter capacity BSL-3 facility for manufacturing vaccines using its proprietary Vero cell platform. For more information, visit the Company website at www.nanotherapeutics.com.